Abiopharma

MEDICUS PHARMA LTD. (MDCX)

Symbol	MDCX
Name	MEDICUS PHARMA LTD.
Sector	UNDEFINED
Region	North America
Industry	Pharmaceutical Preparations
Address	300 CONSHOHOCKEN STATE ROAD SUITE 200, CONSHOHOCKEN, Pennsylvania, 19428, United States
Telephone	+1 610 540-7515
Fax	—
Email	—
Website	https://www.medicuspharma.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001997296
Description	Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma. Additional info from NASDAQ: Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma.

2026-06-22 11:30

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

2026-06-15 11:30

Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome

2026-06-11 11:30

Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

2026-06-08 11:30

Medicus Pharma Advances Teverelix® Program Towards Registrational Development Targeting High Cardiovascular-Risk Prostate Cancer Patients with Key European Submission

2026-06-04 20:30

(70% Positive) MEDICUS PHARMA LTD. (MDCX) Announces Regulatory Update

2026-06-04 20:19

Smith Andrew Alasdair 🟢 acquired 200.0K shares (1 derivative) of Medicus Pharma Ltd. (MDCX) at $0.36 Transaction Date: Jun 03, 2026 | Filing ID: 001643

2026-06-04 20:17

Director Rodgers Cathy McMorris 🟢 acquired 50.0K shares (1 derivative) of Medicus Pharma Ltd. (MDCX) at $0.36 Transaction Date: Jun 03, 2026 | Filing ID: 001642

2026-06-04 20:16

Director Raju Ajay 🟢 acquired 50.0K shares (1 derivative) of Medicus Pharma Ltd. (MDCX) at $0.36 Transaction Date: Jun 03, 2026 | Filing ID: 001641

2026-06-04 20:15

Mehmud Faisal 🟢 acquired 250.0K shares (1 derivative) of Medicus Pharma Ltd. (MDCX) at $0.36 Transaction Date: Jun 03, 2026 | Filing ID: 001640

2026-06-04 20:13

Director May Sara R. 🟢 acquired 50.0K shares (1 derivative) of Medicus Pharma Ltd. (MDCX) at $0.36 Transaction Date: Jun 03, 2026 | Filing ID: 001639